Unavailable
Unavailable
Save time and jump to the most important pieces.
DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that it has undertaken a series of transactions to ensure compliance with Nasdaq's continued listing standards. Last year on June 24, 2024, SeaStar Medical received a written notification from Nasdaq's Listing Qualifications Staff that it was not in compliance with the requirement to maintain a minimum market value of listed securities of $35 million as required by Nasdaq Listing Rule 5550(b)(2). After a hearing before the Nasdaq Heari
DENVER, June 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (the "Company" or "SeaStar Medical") (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced the pricing of a public offering of 6,153,847 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 6,153,847 shares of common stock and Series B short-term warrants to purchase up to 6,153,847 shares of common stock, at a combined offering price of $0.65 per share of common stock (or per pre-funded warrant in lieu thereof)
SAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical (NASDAQ:ICU) announced today that a new United States Department of Defense (DoD) grant has been awarded to AREVA. The grant is one of four selected out of 160 total submissions by the 2024 Military Burn Research Program (MBRP) and represents cutting-edge research for extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia. The grant supports a three-year research study that is scheduled to begin in July 2025 with more than $2 million in DoD funding. The study will explore th
SCHEDULE 13G - SeaStar Medical Holding Corp (0001831868) (Subject)
424B4 - SeaStar Medical Holding Corp (0001831868) (Filer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S. A rep
DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. "Our significant accomplishment in 2024 position us well for a transformational year in 2025," said Eric Schlorff, SeaStar Medical CEO. "Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinic
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT Webcast:The live webcast and replay can be found here. Conference ID:2078693 Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside